RICHARD T FREDERICK

Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology SAN FRANCISCO, CA NPI 1720009160

General Payments — all program years on this page

$102,031.73

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 57
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $21,359.01 across 15 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Madrigal Pharmaceuticals $15,032.2711
Mallinckrodt Hospital Products Inc. $3,786.742
Ipsen Biopharmaceuticals, Inc $2,540.002

By program year

Program yearAmountRecords
2018 $5,275.328
2019 $11,420.2311
2020 $32,102.9410
2021 $20,770.007
2022 $5,211.234
2023 $5,893.002
2024 $21,359.0115

Records — PY2024 (15)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1091993089 Ipsen Biopharmaceuticals, Inc $2,490.00 11/27/2024 Honoraria Undisputed 01/23/2026 View at CMS
1091993091 Ipsen Biopharmaceuticals, Inc $50.00 11/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144166150 Madrigal Pharmaceuticals $1,410.00 11/19/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1144166152 Madrigal Pharmaceuticals $3,878.00 12/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1144166154 Madrigal Pharmaceuticals $87.91 12/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144166156 Madrigal Pharmaceuticals $1,323.65 12/05/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1144166158 Madrigal Pharmaceuticals $845.24 12/05/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1144166160 Madrigal Pharmaceuticals $45.00 12/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144166162 Madrigal Pharmaceuticals $210.80 12/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144166164 Madrigal Pharmaceuticals $50.00 12/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144166166 Madrigal Pharmaceuticals $58.09 12/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144166168 Madrigal Pharmaceuticals $73.58 12/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144166170 Madrigal Pharmaceuticals $7,050.00 12/17/2024 Honoraria Undisputed 01/23/2026 View at CMS
1145073048 Mallinckrodt Hospital Products Inc. $3,720.00 09/25/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1145073052 Mallinckrodt Hospital Products Inc. $66.74 11/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.